Clinical application of an in vitro chemosensitivity test, the Histoculture Drug Response Assay, to urological cancers: wide distribution of inhibition rates in bladder cancer and renal cell cancer |
| |
Authors: | Yasuhiro Hirano Tomomi Ushiyama Kazuo Suzuki Kimio Fujita |
| |
Institution: | (1) Department of Urology, Hamamatsu University School of Medicine, 3600 Handa-cho, Hamamatsu City, 431-3192, Japan, JP |
| |
Abstract: | To investigate the variations in chemosensitivity of individual cancers, we performed an in vitro chemosensitivity test,
the Histoculture Drug Response Assay (HDRA), on fresh biopsied or surgical specimens. They were 26 bladder cancers and 19
renal cell cancers. Ten anticancer drugs were tested. By prolonging the drug exposure time to 7 days, we obtained reliable
results. The mean inhibition rates (IRs) were higher for bladder cancer than for renal cell cancer, and the difference was
significant for cisplatin, carboplatin, vinblastine, mitomycin C, and adriamycin. There was no significant correlation between
the histological grade of the tumor and HDRA sensitivity. IR values showed a wide distribution and cancers could be classified
into two groups of sensitive and resistant. This was especially true for 4-hydroxy-ifosfamide. Three bladder cancer patients
with evaluable lesions were treated with drugs selected on the basis of the results of the HDRA. One patient achieved a complete
response and the other patients showed a partial response. Our results suggest that chemosensitivity is independent of the
clinicopathological classification of cancer, and that the HDRA may be useful for selecting the effective anticancer drug
for patients with urological cancer.
Received: 17 July 1998 / Accepted: 25 March 1999 |
| |
Keywords: | Chemosensitivity test Histoculture Drug Response Assay Bladder cancer Renal cell cancer |
本文献已被 PubMed SpringerLink 等数据库收录! |
|